Biocept Inc. ($BIOC) announced its new in-network provider agreement with Blue Cross Blue Shield of Texas, which is the largest health benefits provider in the state. Biocept develops and provides clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients.
The agreement will help the company in further promoting its liquid biopsy approach. Michael Nall, President and Chief Executive Officer of Biocept said that new partnership may help increasing physician’s access to the non-invasive technology for their patients.
The company gained close to 250% in the past five days. However, it is still halfway away from its 52 weeks high of $5.64, offering solid upside potential to the investors.